Social News
Written by: McCain and Li Enci
2020-12-22 19:05
Last update date: 2020-12-22 19:05
Hong Kong intends to purchase three new coronary pneumonia vaccines, one of which is a vaccine produced by China Kexing's inactivated technology.
The third phase of the vaccine's clinical data will be announced tomorrow (23rd), and the Department of Health will review the data in January; The Wall Street Journal first disclosed today that the vaccine's clinical trials in Brazil showed an effective rate of more than 50%.
Respiratory system specialist Liang Zichao explained to "Hong Kong 01" today (22) that the threshold set by the WHO earlier is the effective rate of 50%. "You must pass the minimum standard of 50% efficiency. Experiment. (Numbers) IKEA's talk is equivalent to no talk." I think we must wait until tomorrow's detailed report to evaluate.
He Boliang, director of the Infection and Infectious Diseases Center of the University of Hong Kong, also said that vaccines must pass the 50% threshold. At present, inferences about whether the vaccine's effectiveness reaches 95% are "reliable on estimation."
China Kexing's Kerlaifu vaccine has been in Phase III clinical trials in Brazil, Indonesia, Turkey and China earlier.
(Associated Press)
According to an exclusive report from the Wall Street Journal today, the third phase clinical trial of Coxing’s Kellyf vaccine in Brazil showed an effective rate of more than 50%. Experts expect that the effective rate of the vaccine will reach 95%, which is comparable to those produced by other pharmaceutical companies. New crown vaccine.
In addition to Brazil, Kexing is also conducting Phase III clinical trials in Indonesia, Turkey and China. The trial in Indonesia also found that the vaccine's serum antibody positive conversion rate was 97%.
An effective rate of 50% is only the minimum standard of the WHO
Liang Zichao replied to the report today, thinking that the "effective rate higher than 50%" mentioned in the report was expected.
He said: "The WHO set a threshold at the time of 50% efficiency. You must pass the minimum standard of 50% efficiency. You can continue to experiment first. (Number) IKEA's talk means nothing."
Regarding the report quoted experts inferring that the effective rate of the vaccine would reach 95%, Liang Zichao said: "There are also more than 90%. Everyone naturally hopes that (Kierleford Vaccine) will be up and down." He admitted that only tomorrow Kexing's public data will only "open estimates."
Serum antibody positive conversion rate is not equal to effective rate. Antibody does not necessarily prevent disease
The data shows that the positive conversion rate of vaccinated serum antibody is 97%, how should we understand it?
Liang Zichao explained that the data only reflects that 97% of the participants have produced antibodies after vaccination, but it does not mean that the antibodies in the body can be at a high level and can neutralize the invasion of the virus. Therefore, it cannot be said that the serum antibody positive conversion rate is equal to Effectiveness of the vaccine.
Another expert, He Boliang, also pointed out that the new crown vaccine must pass the 50% efficiency threshold. Discussing the effectiveness of the vaccine without actual data is "by estimation." It must be left to tomorrow's data for comment.
Kexing recruited 24,530 participants in the third phase of clinical trials in 4 regions. As for Pfizer and Modena, the sample sizes were 43,998 and 33,000, respectively.
He Boliang said that Kexing’s experiments were about the same number as the other two, which did not affect accuracy.
However, he agrees that the larger the number of participants, the more accurate it will be. Taking Pfizer’s earlier data as an example, the statistics of participants over 65 years old alone showed that 19 of the infected people were vaccinated with a placebo and another was vaccinated. The entire base is low, so it will reduce the actual effectiveness of the entire vaccine. "Participants above 60 are difficult to get because they are afraid of the danger, so they may not know the true effect."
▼Hong Kong government announces tightening of epidemic prevention measures (announced on December 8)▼
+8
+8
+8
New crown vaccine | Allergy Association: Vaccine allergy is rare, one person per million is severely allergic
British variant virus | He Boliang: A vaccine is believed to be effective if a reagent is sensitive or insufficient
The University of Hong Kong receives a private investment of 1 billion yuan to set up the first local vaccine factory.
Eight of the world's top ten pharmaceutical companies settled in Singapore
01News
New crown pneumonia vaccine